Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies | Zendy

Sharon Lie Fong | Zendy; P.J. Lugtenburg | Zendy; Izaäk Schipper | Zendy; Axel P. N. Themmen | Zendy; Frank H. de Jong | Zendy; Pieter Sonneveld | Zendy; Joop S.E. Laven | Zendy

Open Access

Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies

Author(s) -

Sharon Lie Fong,

P.J. Lugtenburg,

Izaäk Schipper,

Axel P. N. Themmen,

Frank H. de Jong,

Pieter Sonneveld,

Joop S.E. Laven

Publication year - 2008

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/dem392

Subject(s) - anti müllerian hormone , ovarian reserve , chemotherapy , premature ovarian failure , medicine , fertility preservation , ovarian cancer , oncology , ovary , radiation therapy , hormone , cancer , gynecology , endocrinology , fertility , biology , infertility , pregnancy , population , environmental health , genetics

In female cancer survivors, the accelerated loss of primordial follicles as a result of gonadal damage may lead to premature ovarian failure (POF). However, the extent of the damage is unpredictable. Anti-Müllerian hormone (AMH) constitutes a sensitive marker of ovarian reserve. Serum AMH levels were measured to assess sub-clinical ovarian damage in patients treated with gonadotoxic therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research